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See Article, pages 1256–1264Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infec-
tions are major public health problems. Approximately 350–400
million people worldwide are chronic hepatitis B surface antigen
(HBsAg) carriers, and HBV is a leading cause of cirrhosis and
associated liver failure, hepatocellular carcinoma (HCC) and
death. Indeed, one half to one million deaths are estimated to
be related to HBV every year [1]. HCV infects an estimated
130–170 million persons worldwide and is responsible for
350,000–500,000 deaths per year [2,3]. In Europe, where an esti-
mated 7.3–8.8 million people are infected with HCV, the overall
prevalence of the infection is 1.1–1.3%, ranging from 0.6% in
Germany to 4% in Italy [4,5]. Chronic hepatitis C is one of the
main causes of HCC and the most common indication for liver
transplantation in many European countries.
Great progress has been made in the management of chronic
hepatitis B and C at the individual level. Thanks to recent thera-
peutic advances, current treatments are able to control HBV repli-
cation and to eradicate HCV in almost all cases. Thus, further
improvements in the management of HBV and HCV infections
will be possible mainly by focusing on treatment impact at a pop-
ulation level. In this ﬁeld, attention should be given to the
dynamics of infection, natural history, screening, and therapeutic
access which inﬂuence the impact of antiviral therapy on morbid-
ity and mortality [4,5].
The epidemics of HBV and HCV are continuously evolving,
mainly because of increased safety of blood donations, improve-
ments in health care conditions, continuous expansion of intra-
venous drug use, and immigration to Europe from endemic
areas. Thanks to vaccination programs and blood donor testing,
the incidence of HBV infection has decreased signiﬁcantly in
Europe and the United States (US) during the past two decades
[6]. However, this has not translated into a reduced HBV burden,
since the absolute number of HBsAg-positive persons continues
to increase [6,7]. Regarding HCV infection, despite a markedJournal of Hepatology 20
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Open access under CC BY-NC-ND license.decrease in the incidence of new HCV infections since the begin-
ning of the 1990s due to systematic testing of blood donations, it
is anticipated that the incidence of cirrhosis and HCC will con-
tinue to increase over the next decade [4,8]. However, although
chronic hepatitis C is a curable disease, treatment uptake rates
have remained low. The reasons are manifold and include ﬁnan-
cial issues, fear of possible side effects of interferon-based thera-
pies and low detection rates. On the other hand, prognostic
models have demonstrated that combined improvements in
screening, treatment access, and sustained virological response
(SVR) rates have a much greater impact on HCV-related mortality
than the improvement of SVR rates alone [4,9–11].
Screening is a prerequisite to improve access to care. Current
national and international guidelines for the management of HCV
infection recommend that screening for HCV infection should be
performed in individuals with well-known risk factors (risk-
based screening) or individuals within a certain age group (birth
cohort screening) [12,13]. Although data are limited, it is esti-
mated that around 50% of infected persons were identiﬁed in
Europe in 2011, ranging from 34–35% in the United Kingdom
and Spain to 64% in France [4]. In the US, a similar estimated
45–85% of HCV-infected individuals are unaware of their infec-
tion [14,15]. These data indicate that current recommendations
for screening individuals with a known risk factor are not as
effective as they should be. In line with these data, a recent study
observed that in one third of patients in whom a diagnosis of HCV
infection was just made, a blood transfusion received before 1990
was documented as the route of transmission, which demon-
strates the gap existing between the theoretical efﬁcacy of a
screening strategy based on the presence of a common risk factor
and its applicability in real life [16].
These ﬁndings underline the need for new screening policies.
For HCV infection, much interest has recently been given to birth
cohort screening. The rationale for this is evident when con-
sidering the epidemiology of the infection. In Europe as well as
in the US, most infections occurred by blood transfusion in the
late 1980s, before blood products were systematically screened
for HCV. Accordingly, those who were susceptible to receive
blood products before 1990 were at the highest risk of being
infected. Recent epidemiological data in the US indicated that15 vol. 62 j 1225–1227
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individuals born between 1945 and 1965 represent one fourth of
the general population but harbor three fourths of HCV infec-
tions. Consequently, the Centers for Disease Control and
Prevention recommended screening of this age group [14,15].
With full implementation of this strategy, 800,000 persons cur-
rently unaware of their HCV infection are expected to be identi-
ﬁed and thus potentially eligible for treatment. It is unknown if
similar screening strategies could be applied to other countries.
In this issue of the Journal, Wolffram and colleagues assessed
the prevalence of HBV andHCV infections in a primary care setting
in Germany [17]. They investigated a large cohort of individuals
attending their primary care physician for a general check-up. By
doing so, the authors did not identify an age group with a particu-
larly high prevalence of HBV or HCV infection and concluded that
immigration, infection in household or male gender for HBV, and
immigration, intravenous drug use or a history of blood transfu-
sion before 1992 for HCV helped to identify previously unknown
infected persons. These results deserve several comments.
Firstly, this study is remarkable for a number of reasons: It
includes a huge cohort of more than 21,000 persons included in
a preventive medical program in 51 primary care practices. A
high proportion of individuals who attended their physicians
accepted to participate to this study. The authors focused on
the best strategy for identifying individuals unaware of their
infection, which is relevant from a public health point of view.
As previously noted, this study found that blood transfusion
before 1992 was still a common route of transmission in patients
unaware of their HCV infection in 2012. However, this study also
has a limitation, as acknowledged by the authors: it suffers from
a selection bias, as individuals had to attend their general practi-
tioner to have a chance to be included in the study. In addition,
this study was restricted to persons with an appropriate medical
insurance older than 35 years, and few patients older than
75 years were included. Thus, the conclusions of this study apply
to the study population, which is not fully representative of the
general population. This bias is frequent and almost unavoidable
in this kind of epidemiological studies.
With this limitation taken into account, should a birth cohort
screening strategy for the screening for chronic viral hepatitis be
dismissed in Germany? Differences in dynamics and natural his-
tory of HCV infection could explain why a birth cohort strategy
could be efﬁcient in one country and not another. Such differ-
ences explain substantial discrepancies between European coun-
tries in terms of HCV burden. As an example, the peak of the HCV
epidemic in Italy occurred 20–30 years earlier than in other
European countries and was mainly associated with unsafe inva-
sive procedures such as vaccinations or injections of antibiotics
and vitamins [4]. In the United Kingdom, intravenous drug use
seems to be a more frequent route of transmission than in other
parts of Europe [4]. However, available data indicate that the epi-
demiology of HCV infection follows a comparable course in the
US and in several European countries including Germany,
Belgium and France [4,5]. In these countries, the peak of HCV
infections was observed in the late 1980s, and the majority of
new infections are since related to intravenous drug use and
immigration from countries of high HCV prevalence. Thus,
Germany seems to present a similar pattern of the HCV epidemic
as compared to the one predicted by Davis and colleagues in the
US [4,9]. In an attempt to explain differences that could exist
between Germany and the US, the authors advocated that the
population they screened comprised a lower proportion of1226 Journal of Hepatology 2015non-Hispanic Black or Mexican Americans, two populations with
high HCV prevalence. Overall, the question as to whether birth
cohort screening may be useful for the screening for HCV infec-
tion in the general German population remains open.
Additional epidemiological studies including large samples of
individuals representative of the whole population are still
needed. Independently from their outcome, screening based on
known risk factors will always remain indicated.
Up until now, therapeutic guidelines have mainly been elabo-
rated for patient care at an individual level while little attention
has been given to treatment impact at a population level. New
public health policies should aim to improve HBV and HCV
screening to reduce the burden of these infections. While
Wolffram and colleagues have to be commended on their impor-
tant contribution, additional studies will be required to settle the
issue of risk based vs. birth cohort screening in Europe and to
inform decision making for health policies.Conﬂict of interest
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